Non Small Cell Lung Cancer Clinical Trials in Fairfax, Virginia

51 studies are recruiting for non small cell lung cancer in Fairfax, Virginia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

   The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Virginia Cancer Specialists, Fairfax, Virginia

   Locations

   24 in total

   Run by

   Teligene US

   See if you can join NCT06010329 on ClinicalTrials.gov

2. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

   This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Inova Schar Cancer, Fairfax, Virginia

   Locations

   366 in total

   Run by

   BioNTech SE

   See if you can join NCT06712316 on ClinicalTrials.gov

3. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

   Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Virginia Cancer Specialists, Fairfax, Virginia

   Locations

   141 in total

   Run by

   ArriVent BioPharma, Inc.

   See if you can join NCT07185997 on ClinicalTrials.gov

4. Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

   Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) muta…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Virginia Cancer Specialists, PC, Fairfax, Virginia

   Locations

   203 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT07195695 on ClinicalTrials.gov

5. A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

   Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. Researchers want to learn if calderasib (MK-1084) can be given with durvalumab, an immunotherapy, to treat NSCLC after chemotherapy and radi…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Virginia Cancer Specialists ( Site 0114), Fairfax, Virginia

   Locations

   107 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07554339 on ClinicalTrials.gov

6. First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

   Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR or HER2 exon 20 insertion (ex20ins) mutati…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Virginia, Fairfax, Virginia

   Locations

   32 in total

   Run by

   Pierre Fabre Medicament

   See if you can join NCT06043817 on ClinicalTrials.gov

7. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

   This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Virginia, Fairfax, Virginia

   Locations

   60 in total

   Run by

   Synthekine

   See if you can join NCT05098132 on ClinicalTrials.gov

8. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

   The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-l…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Fairfax, Virginia

   Locations

   333 in total

   Run by

   AstraZeneca

   See if you can join NCT06692738 on ClinicalTrials.gov

9. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

   Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology Virginia, Fairfax, Virginia

   Locations

   22 in total

   Run by

   Astellas Pharma Inc

   See if you can join NCT07094204 on ClinicalTrials.gov

10. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

    The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful. The second part is open to people with non-small cell lung cancer with a specific mutation in the HER2 gene. …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Virginia Cancer Specialists, PC, Fairfax, Virginia

    Locations

    85 in total

    Run by

    Boehringer Ingelheim

    See if you can join NCT04886804 on ClinicalTrials.gov

11. Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

    This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Virginia Cancer Specialists, Fairfax, Virginia

    Locations

    31 in total

    Run by

    Teligene US

    See if you can join NCT05168566 on ClinicalTrials.gov

12. Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

    The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Local Institution - 0165, Fairfax, Virginia

    Locations

    204 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07680790 on ClinicalTrials.gov

13. A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

    This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Virginia Cancer Specialist (NEXT Oncology-Virginia), Fairfax, Virginia

    Locations

    5 in total

    Run by

    Dizal Pharmaceuticals

    See if you can join NCT06905197 on ClinicalTrials.gov

14. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Virginia Cancer Specialists, Fairfax, Virginia

    Locations

    20 in total

    Run by

    Verastem, Inc.

    See if you can join NCT07020221 on ClinicalTrials.gov

15. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

    This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Virginia Cancer Specialists, Fairfax, Virginia

    Locations

    24 in total

    Run by

    Verastem, Inc.

    See if you can join NCT07659782 on ClinicalTrials.gov

16. Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

    This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: * Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6. Part 1A will determine the safety, tolerability, pharmacokinetics (PK), and preliminar…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology Virginia, Fairfax, Virginia

    Locations

    6 in total

    Run by

    Sutro Biopharma, Inc.

    See if you can join NCT07807345 on ClinicalTrials.gov

17. A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult par…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Virginia Cancer Specialists - Fairfax /ID# 272004, Fairfax, Virginia

    Locations

    83 in total

    Run by

    AbbVie

    See if you can join NCT06568939 on ClinicalTrials.gov

18. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well as treatment-naïve, advanced/metastatic non-small cell lung cancer (NSC…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Virginia, Fairfax, Virginia

    Locations

    86 in total

    Run by

    BioNTech SE

    See if you can join NCT07111520 on ClinicalTrials.gov

19. Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

    The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combina…

    Stage

    Phase 2

    Ages

    18 to 95

    Site

    Research Site, Fairfax, Virginia

    Locations

    97 in total

    Run by

    AstraZeneca

    See if you can join NCT05061550 on ClinicalTrials.gov

20. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

    This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tum…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Virginia, Fairfax, Virginia

    Locations

    15 in total

    Run by

    Tango Therapeutics, Inc.

    See if you can join NCT06810544 on ClinicalTrials.gov

21. A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

    The goal of this clinical trial is to evaluate FMC-376 monotherapy and in combination with pembrolizumab in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Virginia Cancer Specialists, Fairfax, Virginia

    Locations

    26 in total

    Run by

    Frontier Medicines Corporation

    See if you can join NCT06244771 on ClinicalTrials.gov

22. A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

    This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of vario…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Research Site, Fairfax, Virginia

    Locations

    83 in total

    Run by

    AstraZeneca

    See if you can join NCT07098338 on ClinicalTrials.gov

23. A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

    This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Virginia Cancer Specialists (Fairfax) - USOR, Fairfax, Virginia

    Locations

    38 in total

    Run by

    Genentech, Inc.

    See if you can join NCT04302025 on ClinicalTrials.gov

24. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Virginia, Fairfax, Virginia

    Locations

    49 in total

    Run by

    Institut de Recherches Internationales Servier

    See if you can join NCT05786924 on ClinicalTrials.gov

25. A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

    A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Fairfax, Virginia

    Locations

    13 in total

    Run by

    AstraZeneca

    See if you can join NCT07115043 on ClinicalTrials.gov